title: Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study.
authors.affiliation: Merck Research Laboratories, West Point, Pennsylvania 09486, USA. shahnaz_shahinfar@merck.com
authors.forename: Shahnaz
authors.initials: S
authors.lastname: Shahinfar
authors.forename: Tanya
authors.initials: T
authors.lastname: Dickson
authors.forename: Zhongxin
authors.initials: Z
authors.lastname: Zhang
authors.forename: William F
authors.initials: WF
authors.lastname: Keane
authors.forename: Barry M
authors.initials: BM
authors.lastname: Brenner
mesh_terms: D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000150:complications* / Q000453:epidemiology*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000453:epidemiology* / Q000209:etiology*; D011507:Proteinuria / Q000150:complications; D012307:Risk Factors
chemical_list: D006454:Hemoglobins; D003404:Creatinine